A special symptom of olfactory dysfunction in coronavirus disease 2019: report of three cases

J Neurovirol. 2020 Jun;26(3):456-458. doi: 10.1007/s13365-020-00849-w. Epub 2020 May 18.

Abstract

Three patients of coronavirus disease (COVID-19) showed the symptoms of olfactory dysfunction. Clinical characteristics and treatment were retrospective analyzed. Olfactory disorders are uncommon symptoms of COVID-19 in China. Early diagnosis and intervention are keys to the recovery of olfactory disorders. Particular attention should be devoted to olfactory dysfunction.

Keywords: COVID-19; Olfactory dysfunction.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects
  • Betacoronavirus / pathogenicity
  • COVID-19
  • China
  • Cobicistat / therapeutic use
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / physiopathology*
  • Darunavir / therapeutic use
  • Female
  • Humans
  • Indoles / therapeutic use
  • Male
  • Methylprednisolone / therapeutic use
  • Olfaction Disorders / diagnosis
  • Olfaction Disorders / drug therapy
  • Olfaction Disorders / physiopathology*
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / physiopathology*
  • SARS-CoV-2
  • Taste Disorders / diagnosis
  • Taste Disorders / drug therapy
  • Taste Disorders / physiopathology*
  • Treatment Outcome
  • Vitamin B 12 / analogs & derivatives*
  • Vitamin B 12 / therapeutic use

Substances

  • Antiviral Agents
  • Indoles
  • umifenovir
  • mecobalamin
  • Cobicistat
  • Vitamin B 12
  • Methylprednisolone
  • Darunavir